Tag: Patents
Reverse Payments After Actavis
John Bigelow, Sep 30, 2013
Thirteen years ago-in 2000-the Federal Trade Commission ("FTC") and private plaintiffs began fighting certain kinds of settlements that sometimes arise...
The Evolution of U.S. Antitrust Agencies’ Approach to Standards and Standard...
This article is part of a Chronicle. See more from this Chronicle
James Rill, Sep 16, 2015
The focus of this article is on what has...
Reverse Payments Post Actavis: A Litigation Quagmire?
This article is part of a Chronicle. See more from this Chronicle
Keith Hylton, Jul 15, 2015
For the last decade or so, the FTC has...
Standard Setting, Patents, and Competition Law Enforcement—The Need for U.S. Policy...
This article is part of a Chronicle. See more from this Chronicle
Alden Abbott, Mar 16, 2015
The setting of industry standards is widely recognized as...
Antitrust Regulation of IPRs: China’s First Proposal
Aug 14, 2014
CPI Asia Column edited by Vanessa Zhang (Global Economics Group) presents:
Antitrust Regulation of IPRS – China’s First Proposal - Adrian Emch (Hogan...
What You Need To Know About Standard Essential Patents
This article is part of a Chronicle. See more from this Chronicle
Michael Carrier, Aug 22, 2014
In the past several years, standard essential patents, or...
New Jersey District Court Limits Actavis To Cash Payments
This article is part of a Chronicle. See more from this Chronicle
Donald Falk, Christopher Kelly, Apr 29, 2014
As with patent infringement litigation in many...
Appropriating the Returns from Industrial Research and Development (1950)(reprint)
Dec 20, 2013
To have the incentive to undertake research and development, a firm must be able to appropriate returns sufficient to make the investment...
An Introduction to Appropriating the Returns from Industrial Research and Development
David Evans, Dec 20, 2013
There are several areas of economics where we know much more today than we did 50 years ago as a...
Pay-for-Delay
Fiona Scott Morton, Dec 20, 2013
This article lays out the economics of competition between branded and generic pharmaceuticals and its welfare consequences. I explain...
